Vir Biotechnology

Vir Biotechnology Employees

10 people indexed:

Aine Hanly

Executive Vice President and Chief Technology Officer

2mgzw8@75x.d6c Sign up to see email

81c3m5@ze7.uqx Sign up to see email
Amalio Telenti

Executive Vice President and Senior Research Fellow

7w38s9z6@732.kws Sign up to see email

mg8jp65h@9wu.dgk Sign up to see email
Antonio Lanzavecchia

Senior Vice President and Senior Research Fellow

0smu1qp9d43yj@6yt.7k7 Sign up to see email

j1j57f0467pup@2f4.9k4 Sign up to see email
Carey Hwang

Senior Vice President of Clinical Research & Interim Chief Medical Officer

1z7j4u@6ms.mxm Sign up to see email

1p3kqx@q12.541 Sign up to see email
Jennifer Eileen Towne

Executive Vice President and Chief Scientific Officer

0dm2dpx.dcddz@ap1.hy3 Sign up to see email

6sddy62.a12x9@yq4.s86 Sign up to see email
Jenny Gumm

Executive Vice President, Chief Human Resources Officer

05fzk@n53.w2e Sign up to see email

3z7s9@y5x.7x3 Sign up to see email
Lynne Krummen

Executive Vice President, Regulatory and Program Leadership

aytza311@4z3.83t Sign up to see email

cfwc28ja@pt0.a6g Sign up to see email
Marianne De Backer

Chief Executive Officer and Director

6u1.fgxq9y@3lq.lww Sign up to see email

htw.9hq57y@y9u.u4n Sign up to see email
Ruju Bhatt Srivastava

Executive Vice President, Program Leadership and Management

7zdz6w.4uf5cmq27n@59n.jfm Sign up to see email

pz69wd.8pcxnym98m@090.cck Sign up to see email
Vanina de Verneuil

Executive Vice President, General Counsel and Corporate Secretary

4km.ty20f783@kkm.t5z Sign up to see email

5ct.sag40gj8@q64.as7 Sign up to see email

Vir Biotechnology Company Information

Vir Biotechnology, based in San Francisco, CA, with additional facilities in Portland, OR, and Bellinzona, Switzerland, focuses on the development of innovative treatments for infectious diseases. The company utilizes a proprietary monoclonal antibody platform and a T cell-based viral vector platform to develop drugs that address diseases with significant unmet medical needs, including chronic hepatitis B and D, influenza, and COVID-19. Vir Biotechnology has successfully developed two commercial medicines: sotrovimab for COVID-19 and ansuvimab-zykl for Ebola. The company’s pipeline includes multiple clinical-stage and preclinical candidates. Furthermore, Vir Biotechnology enhances its drug discovery and development processes by integrating artificial intelligence into antibody optimization and engineering. The company also actively collaborates with renowned global institutions and researchers to propel scientific advancements in the field.

Report inaccurate information